Biomea Fusion, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 28, 2024. The filing also presents unaudited fourth-quarter results. Biomea Fusion is a clinical-stage biotechnology company developing oral covalent small-molecule therapies. It has no approved products and has generated no revenue.
Financial performance and position
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $102.5 million | $62.7 million |
| General and administrative expense | $23.6 million | $20.9 million |
| Total operating expenses / operating loss | $126.1 million | $83.6 million |
| Interest and other income, net | $8.9 million | $1.8 million |
| Net loss | $117.3 million | $81.8 million |
| Net loss per share, basic and diluted | $3.44 | $2.80 |
| Net cash used in operating activities | $96.6 million | $62.4 million |
Fourth quarter: Operating expenses were $37.3 million and net loss was $34.9 million, compared with $26.3 million and $25.3 million, respectively, in Q4 2022. Q4 2023 R&D expense was $30.9 million and G&A expense was $6.5 million.
Liquidity and capital: At year-end, cash and cash equivalents were $176.9 million, restricted cash was $0.4 million, and total current assets were $179.2 million versus current liabilities of $22.9 million. Total assets were $199.9 million; total liabilities were $30.7 million, including $10.3 million of operating lease liabilities. The company had no interest-bearing liabilities. A public offering in April 2023 raised $161.8 million net from 5.75 million shares. Accumulated deficit was $248.8 million.
Material changes and business developments
- R&D expense rose $39.8 million year over year, principally from increased clinical-trial activity, personnel, and facilities costs. G&A expense increased $2.7 million. Higher interest income partially offset the larger operating loss.
- Operating cash use increased $34.2 million year over year. Cash and restricted cash increased by $65.0 million, primarily reflecting the 2023 equity offering.
- BMF-219, a covalent menin inhibitor, was in trials for type 2 diabetes, type 1 diabetes, liquid tumors, and KRAS-mutant solid tumors. BMF-500, a covalent FLT3 inhibitor, entered its first clinical trial in relapsed or refractory acute leukemia in October 2023.
Outlook, commentary, and risks
- Going concern: Management concluded there is substantial doubt about the company’s ability to continue as a going concern. It stated year-end resources, without additional financing, would not fund operations for at least twelve months from the financial statements’ issuance. Additional capital is required; availability and terms are uncertain.
- Management expects significant losses and expenses to continue and increase as trials and development programs advance. No quantitative revenue or earnings guidance is provided.
- Management expected to nominate a third development candidate and complete dose escalation or select recommended Phase 2 doses for BMF-219 oncology trials and BMF-500 in 2024. Initial proof-of-concept data for BMF-219 in type 1 diabetes were also expected in 2024.
- The filing reports preliminary, small-cohort BMF-219 findings, including glycemic improvements in type 2 diabetes and early responses in AML. These results are not evidence of established efficacy: data may change with further follow-up, and larger trials are needed. Reported AML responses included differentiation syndrome in four participants, managed with treatment; no dose-limiting toxicities were reported to date.
- Key risks include clinical and regulatory uncertainty, potential safety issues, competition, dependence on third-party manufacturers and single-source suppliers, and the need for additional financing that could dilute shareholders or constrain programs. The company had no material legal proceedings. The auditor issued an unqualified opinion on the financial statements but highlighted the going-concern uncertainty.
Important facts for investors to verify
- Cash runway assumptions and the timing, amount, and terms of any financing; reconcile management’s less-than-12-month funding statement with cash, cash burn, and planned trial expansion.
- Updated clinical-trial data, enrollment, durability, safety, and regulatory feedback for BMF-219 and BMF-500; distinguish preliminary company-reported results from confirmed outcomes.
- Expected trial costs and whether planned programs can proceed without additional capital or program reductions.
- Potential dilution from future equity issuance and outstanding options; common shares outstanding were 35.9 million at year-end, with 7.36 million options outstanding.
- Manufacturing continuity and reliance on external and certain single-source suppliers, including suppliers outside the United States.